Canine status epilepticus: A translational platform for human therapeutic trials

Ilo E. Leppik; Edward N. Patterson; Lisa D. Coles; Elise M. Craft; James C. Cloyd

doi:10.1111/j.1528-1167.2011.03231.x

Canine status epilepticus: A translational platform for human therapeutic trials

Ilo E. Leppik, Edward N. Patterson, Lisa D. Coles, Elise M. Craft, James C. Cloyd

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.

Original language	English (US)
Pages (from-to)	31-34
Number of pages	4
Journal	Epilepsia
Volume	52
Issue number	SUPPL. 8
DOIs	https://doi.org/10.1111/j.1528-1167.2011.03231.x
State	Published - Oct 2011

Keywords

Canine epilepsy
Status epilepticus
Translational platform

Access

10.1111/j.1528-1167.2011.03231.x

OpenUrl availability

Full text

Cite this

@article{a530d0fb925a4388a06cf4c30b3fdf35,

title = "Canine status epilepticus: A translational platform for human therapeutic trials",

abstract = "Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.",

keywords = "Canine epilepsy, Status epilepticus, Translational platform",

author = "Leppik, {Ilo E.} and Patterson, {Edward N.} and Coles, {Lisa D.} and Craft, {Elise M.} and Cloyd, {James C.}",

year = "2011",

month = oct,

doi = "10.1111/j.1528-1167.2011.03231.x",

language = "English (US)",

volume = "52",

pages = "31--34",

journal = "Epilepsia",

issn = "0013-9580",

publisher = "Wiley-Blackwell",

number = "SUPPL. 8",

}

TY - JOUR

T1 - Canine status epilepticus

T2 - A translational platform for human therapeutic trials

AU - Leppik, Ilo E.

AU - Patterson, Edward N.

AU - Coles, Lisa D.

AU - Craft, Elise M.

AU - Cloyd, James C.

PY - 2011/10

Y1 - 2011/10

N2 - Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.

AB - Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.

KW - Canine epilepsy

KW - Status epilepticus

KW - Translational platform

UR - http://www.scopus.com/inward/record.url?scp=80053590410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053590410&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2011.03231.x

DO - 10.1111/j.1528-1167.2011.03231.x

M3 - Article

C2 - 21967357

AN - SCOPUS:80053590410

SN - 0013-9580

VL - 52

SP - 31

EP - 34

JO - Epilepsia

JF - Epilepsia

IS - SUPPL. 8

ER -

Canine status epilepticus: A translational platform for human therapeutic trials

Abstract

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this